Study: More Herpes Strains are Resistant to Acyclovir; polyDNA recommends Gene-Eden-VIR, a Natural Antiviral against Many Latent Herpes Strains

July 12, 2013

Viral resistance toward Acyclovir, which has been used for more than 20 years, is on the rise according to a study published in the Proceedings of the National Academy of Sciences (PNAS) in April 2013. (1) polyDNA recommends Gene-Eden-VIR, a natural antiviral, against latent herpes.

Rochester, NY (PRWEB) July 12, 2013

Acyclovir and related drugs are the current drugs of choice for the treatment of herpes infection and viral reactivation. Now, a new study, which builds upon previous research, showed that the herpes virus is becoming resistant to the most commonly prescribed antiviral drugs, including ACV. (1)

People with a healthy immune system are usually able to control the HSV virus and keep it from becoming more than an occasional, painful annoyance. People with a healthy immune system have herpes outbreaks that rarely last more than two weeks, and their herpes sores are small and short lived. However, another study said that, “In contrast, immunocompromised patients might not be able to control HSV infection.” (Dermatologic Clinics, 2003) (2)

This means that someone who has a weakened immune system is at risk for longer and more painful herpes outbreaks. In these people, “frequent and severe reactivations are often seen.” (2) This happens for two reasons. The first is that the person’s immune system is weak. The second is because the virus has built resistance against the most commonly prescribed antiviral drugs. The over prescription of anti-herpes medications has given the herpes virus an opportunity to mutate and develop a resistance to those drugs.

Due to the frightening and ever increasing presence of drug resistant herpes strains, polyDNA proposes the use of a clinically backed, natural herpes remedy called Gene-Eden-VIR. This remedy is effective against the latent herpes virus and is not overly prescribed by medical professionals.

“The implications of herpes strains that are resistant to the drugs most commonly prescribed by doctors should be clear to everyone. When these drugs are no longer effective, people will have to suffer longer and more painful herpes outbreaks. The answer to this problem is to move away from these drugs. It’s time to make a move toward products that are naturally antiviral, and that have already been shown to be effective against the herpes virus.” –Mike Evans, polyDNA

Doctors should recommend Gene-Eden-VIR to their patients and make it a part of their anti-herpes regimen. The herpes virus has shown no resistance to the natural ingredients that make up this product.

Each ingredient was chosen through a scientific approach and the product is made up of only the safest, most effective natural ingredients that target the latent form of herpes. (3)

In addition, a recent post marketing clinical study showed that Gene-Eden-VIR is safe and effective. Up to 70% of those studied reported a decrease in viral symptoms. (4)

To learn more about Gene-Eden-VIR and herpes, visit http://www.gene-eden-kill-virus.com/Herpes-Remedy.php. All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.


(1) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637765/

(2) http://www.ncbi.nlm.nih.gov/pubmed/12757254

(3) http://gene-eden-kill-virus.com/studies.php

(4) http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/7/prweb10914593.htm

Source: prweb

comments powered by Disqus